XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box

Recall Number: D-1250-2014

Firm: Dolphin Intertrade Corporation

Classification: Class I

Status: Terminated

Report Date: 20140430

Initiation Date: 20130520

Termination Date: 20160629

Reason for Recall

Marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.

Product Description

XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box

DrugLabelsHub provides FDA drug labeling information for reference only. Always consult a healthcare professional.

Data source: openFDA · Updated regularly